SpeeDx Raise US $15 million Equity from Northpond Ventures
Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets....
Up to 15 million equity investment from US-based Northpond Ventures will accelerate commercial expansion in North America and global markets....
This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy...
SpeeDx signed a collaboration agreement with GSK to provide tests and custom test development to support antibiotic clinical trials...
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Designation for ResistancePlus® GC - expediting the path towards clearance....
PlexPCR® RespiVirus received clearance from the Australian Therapeutic Goods Administration (TGA), bringing much needed workflow advantages in time for the...
Dr. Klausner, a clinical professor at UCLA, shares the details of his work with genotypic testing for ciprofloxacin susceptibility in...